FluBlok, a recombinant hemagglutinin influenza vaccine.
FluBlok, a recombinant hemagglutinin influenza vaccine.
复制标题
DOI：
10.1111/j.1750-2659.2008.00053.x
复制
发表时间：
2008-11
影响因子：
4.4
通讯作者：
Treanor J
中科院分区：
文献类型：
--
作者：
Cox MM;Patriarca PA;Treanor J
摘要 流感疫苗是一种利用杆状病毒表达系统在昆虫细胞培养中生产的重组三价血凝素疫苗，它为目前以鸡蛋为基础的三价流感灭活疫苗的生产工艺提供了一种有吸引力的替代方案。Flublok含有的HA是TIV的三倍，不含鸡蛋蛋白或防腐剂。这篇综述讨论了四项主要的临床研究，这些研究被用来支持在美国的“加速批准”机制下的福尔布洛克的许可。
Abstract FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg‐based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg‐protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the ‘Accelerated Approval’ mechanism in the United States.